Antioxidant Resveratrol May Help Reduce Arteriosclerosis in T2DM

Share this content:
Antioxidant Resveratrol May Help Reduce Arteriosclerosis in T2DM
Antioxidant Resveratrol May Help Reduce Arteriosclerosis in T2DM

FRIDAY, May 5, 2017 (HealthDay News) -- Resveratrol appears to reduce arteriosclerosis in patients with type 2 diabetes, according to findings presented at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology/Peripheral Vascular Disease 2017 Scientific Sessions, held from May 4 to 6 in Minneapolis.

Naomi Hamburg, M.D., chief of the vascular biology section at the Boston University School of Medicine, and colleagues measured the aortic thickness of 57 patients with type 2 diabetes (age 56 and obese, on average). The investigators also conducted tests to measure blood-vessel function. Some patients were given resveratrol supplements, while the others were given a placebo.

Overall, the team found a trend toward less arterial stiffness in participants taking resveratrol supplements, but it wasn't statistically significant. However, in a subset of 23 patients with high arterial stiffness at the start of the study, 100-mg daily doses of resveratrol for two weeks reduced stiffness 4.8 percent. That regimen was followed by 300-mg doses over two weeks, which decreased stiffness by 9.1 percent. Arterial stiffness increased among those taking a placebo for four weeks.

In animal studies, Hamburg told HealthDay, resveratrol has been shown to activate the SIRT1 gene that appears to delay aging and development of several diseases. To assess the correlation in humans, the researchers took samples from the blood-vessel linings of seven patients and looked at SIRT1 activity. They found that gene activity increased slightly after resveratrol supplementation.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths